First studies from 2017, carried out in syngeneic and xenograft acute myeloid leukemia (AML) models, have already demonstrated that CAR-T cells secreting constitutive IL-18 boost their proliferation and antitumor activity compared to anti-CD19 or anti-mesothelin CARs alone by recruiting a second wave of immune cells to the TME.41 Here, MSLN is linked to acute myeloid leukemia.